Cancer screening uses a range of tests to look for signs of cancer before symptoms appear. The specific test depends on the type of cancer, and recommendations vary by age, sex, and personal risk factors. Most screening applies to just a handful of cancers where catching the disease early has been proven to improve survival: breast, colorectal, cervical, lung, and prostate.
Breast Cancer Screening
Mammography is the standard screening tool for breast cancer. It’s a low-dose X-ray of the breast that can detect tumors too small to feel. Current guidelines recommend women get a mammogram every two years from age 40 through 74.
Most facilities now offer 3D mammography, which takes images from multiple angles and assembles them into a layered picture of the breast tissue. This approach catches more cancers, especially small ones, and reduces the number of false alarms that lead to stressful callbacks for additional imaging.
False positives are common with mammography, particularly for younger women. Among women in their 40s, roughly 12 out of every 100 screening mammograms produce a false positive result, meaning you get called back for extra imaging or a biopsy that ultimately shows no cancer. That rate drops with age, falling to about 7 per 100 for women in their 70s. This doesn’t mean screening isn’t worth it, but it’s useful to know that a callback after a mammogram is more likely to be a false alarm than an actual cancer diagnosis.
Colorectal Cancer Screening
Screening for colorectal cancer is recommended for all adults starting at age 45 and continuing through age 75. There are two main approaches: stool-based tests you can do at home and direct visualization of the colon.
The simplest option is a stool test called a fecal immunochemical test, or FIT. You collect a small stool sample at home and mail it to a lab, where it’s checked for hidden traces of blood that could signal polyps or cancer. FIT is painless and convenient, but it has a meaningful limitation: it catches only about 25% of advanced precancerous growths on any single test. That’s why it needs to be repeated every year to be effective over time.
Colonoscopy is the most thorough option. A doctor uses a flexible camera to examine the entire colon, and any precancerous polyps found during the procedure can be removed on the spot. Because it’s so comprehensive, a colonoscopy with normal results typically doesn’t need to be repeated for 10 years. The tradeoff is that it requires a full day of bowel preparation, sedation during the procedure, and a recovery period afterward.
Other options fall somewhere between these two. A stool DNA test combines the blood detection of FIT with genetic markers and is done every three years. A CT colonography (sometimes called a virtual colonoscopy) uses imaging instead of a camera and is repeated every five years. Your choice often comes down to what you’re willing to do consistently, since the best screening test is the one you actually complete.
Cervical Cancer Screening
Cervical cancer screening starts at age 21 and continues through age 65. The approach changes depending on your age because the biology of the cervix shifts over time.
For women ages 21 to 29, the recommendation is a Pap smear every three years. A Pap smear collects cells from the cervix so a lab can check for abnormal changes that could become cancer if left untreated. HPV testing isn’t routinely recommended in this age group because HPV infections are extremely common in younger women and almost always clear on their own.
Starting at age 30, you have three options: a Pap smear every three years, an HPV test every five years, or both tests together every five years. The HPV test checks for the specific virus strains most likely to cause cervical cancer. Because HPV testing is more sensitive, it can safely be done less frequently. Screening more often than these intervals doesn’t meaningfully improve detection but does increase the chance of unnecessary procedures like colposcopy, where a doctor takes a closer look at the cervix under magnification.
Lung Cancer Screening
Lung cancer screening is different from most other screenings because it’s only recommended for people with a significant smoking history. The test is a low-dose CT scan of the chest, done once a year for adults aged 50 to 80 who have a smoking history of 20 pack-years or more and who either still smoke or quit within the past 15 years.
A pack-year is a way of measuring cumulative exposure. One pack-year equals smoking one pack per day for one year. So 20 pack-years could mean one pack a day for 20 years, or two packs a day for 10 years. If you fall below that threshold or quit more than 15 years ago, the potential harms of annual CT scanning (radiation exposure, false positives leading to invasive follow-up procedures) outweigh the benefits.
The low-dose CT scan takes just a few minutes and doesn’t require any preparation. It produces detailed cross-sectional images of the lungs that can reveal small nodules. Most nodules turn out to be benign, which is why follow-up imaging or biopsy is sometimes needed to sort out real threats from harmless findings.
Prostate Cancer Screening
Prostate cancer screening is more nuanced than screening for other cancers. The primary tool is a PSA blood test, which measures levels of a protein produced by the prostate. Elevated PSA can signal cancer, but it also rises with benign conditions like an enlarged prostate or an infection.
For men ages 55 to 69, screening is treated as an individual decision rather than a blanket recommendation. The concern is that PSA testing frequently detects slow-growing cancers that would never cause symptoms or shorten life, and the resulting biopsies and treatments carry real side effects. For men 70 and older, routine PSA screening is not recommended because the risks of overdiagnosis and overtreatment outweigh the potential benefit at that age.
If you’re in the 55 to 69 range, the decision typically involves a conversation about your family history, race (Black men have higher prostate cancer risk), and how you feel about the possibility of further testing and treatment if something abnormal turns up.
Genetic Risk Screening
Some people carry inherited gene mutations that dramatically raise their cancer risk. The most well-known are BRCA1 and BRCA2 mutations, which increase the likelihood of breast and ovarian cancer. Screening for these mutations isn’t recommended for everyone, but it is recommended for women whose personal or family history suggests they might carry one.
Red flags that prompt a genetic risk assessment include breast cancer diagnosed before age 50, cancer in both breasts, a family member with both breast and ovarian cancer, male breast cancer in the family, multiple relatives with breast cancer, and Ashkenazi Jewish ancestry. If a brief screening tool flags you as higher risk, the next step is genetic counseling, where a specialist walks you through what testing involves and what the results could mean for you and your relatives. Genetic testing itself is a simple blood or saliva sample.
A positive result doesn’t mean you have cancer. It means you may benefit from earlier or more frequent screening, like starting mammograms before age 40 or adding breast MRI to your routine.
Skin Cancer Screening
Unlike the cancers above, there is no broadly recommended screening program for skin cancer in the general population. The evidence simply hasn’t shown that routine skin exams by a primary care doctor reduce melanoma deaths in people at average risk. For people with higher risk factors, such as fair skin, a history of severe sunburns, many moles, or a family history of melanoma, dermatologists often recommend periodic full-body skin exams.
Regardless of formal screening, knowing your own skin is valuable. Tracking moles for changes in size, shape, color, or symmetry helps you spot something worth showing a doctor early.
Multi-Cancer Blood Tests
A newer category of screening is the multi-cancer early detection (MCED) blood test, which looks for DNA fragments shed by tumors into the bloodstream. These tests aim to screen for dozens of cancer types with a single blood draw, including cancers like pancreatic and ovarian that have no standard screening test today.
A few MCED tests are currently available, but they come with important caveats. A Mayo Clinic study found that 1 in 4 positive results from an MCED test turned out to be a false positive. A positive result leads to additional imaging and procedures to locate a cancer that may not exist. These tests are not yet recommended as a replacement for established screening programs, and most insurance plans do not cover them.